Anyone else in on this? Fuckin' nuts, and almost certainly not too late to get in on it. 💰

$MGX is a genetics biotech in the gene editing arena. The revenues for it's tools and services are exploding from 17M in 2022, to 45M in 2023 and about 56M TTM which should be much higher at recent the quarterly run rate. The gross profits are over 90%.

If this is correct, then this company is selling at 2X annual gross profits. The rest of the expenses are bloated SG&A and R&D, which may or may not be manageable. If this company grows revenues at the current clip, they would be breaking even 2-3 years, and they have 300M cash on the books to carry them into profitability. This is my quick 5 minute analysis, with all obvious caveats and assumptions attached.

Why is it trading so low around $2 per share? Because soon after it went IPO, MRNA got out of some arrangement with them, and people overreacted about it, so it's down from $12 to $2. While this might have been significant at the time, it is obvious that MRNA has its own issues and is one of the worst performing SP500 stocks. In any event, we are here looking at $MGX at $2+change, not at $12, and our perspective, risk profile, and value proposition from down here is different than it was for those unfortunate investors pre, during and shortly after the IPO. By the way, the scanner I am using will always have this defensive feature, so by definition, I aim to never overpay for a stock compared to other traders.

There has been recent unusual uptick in its trading, and yesterday when I tried to open a position, I saw why. I could not fill a 2000 share order at the ask - the order kept filling partially, and I increased the price twice tog et a fill. The supply of this stock seems to be short and whatever algos are out there working the stock are way too aggressive and bullish, which made me wonder who in interested in the stock for it to move in this way. So, who is buying up the stock?

Well, in February 2024, the world's largest charitable foundation Novo Holdings S/A invested in the stock and was a 10%+ shareholder. Then just last week, I read a seemingly irrelevant and largely ignored filing in which no one other than BAYER has bought more than 4 million shares, or more than 10% steak in the company. Yep, this is that BAYER - one of the biggest biotech companies in the world.

https://archive.fast-edgar.com/20241106/ARB2PG2D8C22HZZA222J2ZZZ5JTK72S2Z262/

Also there are the usual suspect hedge funds, which I will not list but you can check them out in the list of institutional holders. https://finance.yahoo.com/quote/MGX/holders/

To me personally, this stock presents an great risk-return opportunity, and given that we are competing for shares with the largest charity endowments and biotech companies in the world, I think that I can make a good return while they are bidding the stock up. People who follow me probably know that I don't look at companies from my own perspective, but from a second order perspective where I want to be in companies which are appealing to those who have the most money potentially flowing into them, since that is how scarce stock becomes expensive. This company fits that profile perfectly.

Disclosure: currently I own 2000 shares, and I may or may not add more shares, and I will sell these and all other shares as I see fit. Nothing here can be construed as financial advice.

Please do your own research, formulate your own trades, trade small, and be careful.

Cheers!

The wave of excitement in the markets are being reflected, and it is pretty remarkable how bullish things are right now. It feels like anything has a chance to take off and it is really fun to be a part of. Will this type of hype last? Truthfully, probably not… However, I do have a couple of stocks on this watchlist that could really benefit during this unique period in the markets. Both have done quite well this year. One up 14% while the other is up 100%+. 

I recently read an interview with Sean Michael Brehm from Spectral Capital ($FCCN), and they’re doing some exciting work with their Quantum Bridge Program. This initiative is all about supporting quantum computing startups with funding, mentorship, and access to industry partnerships, aiming to accelerate the journey from research to real-world applications. Given the potential of quantum computing in sectors like healthcare, finance, and energy, I wonder how close we are to real breakthroughs that could impact our daily lives. The interesting part? $FCCN is also tackling issues like high costs and limited accessibility in quantum tech, which could be game-changers. I will link more to this at the bottom of this post, but it is definitely a stock to add to your watchlist. Here is some TA for those interested!

Price Action:

• The stock is trading at $5.00, within a horizontal resistance zone near $5.50 and supported at $4.00.
• The ascending trendline support from June 2024 underpins the upward momentum.

Volume:

• Solid, with 10.42K average daily volume.

Indicators:

• The Modified 50-Day Moving Average (blue line) is at $5.30, suggesting short-term downward pressure below the average.
• The MACD (12,26) histogram is close to zero, reflecting consolidation, while the signal lines indicate low momentum.

Pattern:

• A possible ascending triangle is forming (bullish continuation pattern), with resistance near $5.50 and an upward-sloping trendline.
• A breakout above $5.50 could signal a strong upward move, while failure to hold $4.00 might trigger downside risks.

The market is wild right now, so make sure to be careful and continue doing your own research. Communicated Disclaimer: This is not financial advice and continue your DD before investing. Sources - 1, 2, 3

Most of you have heard of this company, a few years ago it went above $1 because Paul Pelosi jr joined as a director. In the three years following, while the SP declined, the company powered ahead and has managed to secure a large facility in an industrial multimodal hub in one of the most populated regions of North America (Southern Ontario). They have also completed the installation, commissioning and environmental approvals for their battery recycling line. They have secured a 3 year battery supply deal from Call2Recycle. They have a green hydrogen process and have partnered with a South Korean company to put into production. News on this is coming soon. They have exploration rights in Quebec with a 43-101 about to be released and they own all rights in Iceland where they recently found gold. They have stated that a major announcement is imminent. Currently trading at only 5 Cents! What is going to happen next??????? Put this one on your watchlist! Good luck! $SXOOF $SX.CN in Canada

ROTH to Host 13th Annual Technology Conference at the Hard Rock Hotel in New York City

Event to feature one-on-one meetings between institutional investors and senior management from over 110 companies across a variety of technology sub-sectors

https://finance.yahoo.com/news/roth-host-13th-annual-technology-140000287.html

Let’s see if this post ages like wine or milk.

• Total Revenue: $46.3 million in Q3 2024, a 15% increase from $40.1 million in Q3 2023.
• Roxadustat Net Product Revenue in China: $46.2 million in Q3 2024, a 57% increase from $29.4 million in Q3 2023.
• Total Roxadustat Net Sales in China: $96.6 million in Q3 2024, a 25% increase from $77.1 million in Q3 2023.
• Operating Costs and Expenses: $63.1 million in Q3 2024, a 39% decrease from $103.6 million in Q3 2023.
• R&D Expenses: $21.7 million in Q3 2024, a 65% decrease from $61.2 million in Q3 2023.
• G&A Expenses: $17.6 million in Q3 2024, a 31% decrease from $25.6 million in Q3 2023.
• Net Loss: $17.1 million in Q3 2024, compared to a net loss of $63.6 million in Q3 2023.
• Cash, Cash Equivalents, and Accounts Receivable: $160 million as of September 30, 2024.
• Guidance for Full Year 2024 China Net Product Revenue: Between $135 million and $150 million.
• Guidance for Roxadustat Net Sales in China: Revised to $330 million to $360 million for full year 2024.
• FibroGen Inc (NASDAQ:FGEN) reported a 57% year-over-year increase in net product revenue for Roxadustat sales in China.
• The company has a solid cash position with $160 million in cash, cash equivalents, and accounts receivable, expected to fund operations into 2026.
• Roxadustat continues to perform well in China, maintaining a 45% market share and showing a 25% increase in total net sales year-over-year.
• FibroGen Inc (NASDAQ:FGEN) is advancing its oncology pipeline with FG-3246 and FG-3180, showing promising efficacy signals in prostate cancer treatment.
• The company has implemented significant cost reduction measures, reducing operating expenses by 39% year-over-year, and transitioning to a virtual work environment.Total Revenue: $46.3 million in Q3 2024, a 15% increase from $40.1 million in Q3 2023.

$MSTR (MicroStrategy)

MicroStrategy has been making headlines with its continued investment in Bitcoin. The company recently purchased an additional 27,200 BTC, bringing its total holdings to over $2 billion. This aggressive strategy has paid off, with MicroStrategy's stock seeing a boost in value as Bitcoin's price soars.

$PEPU (Pepe Unchained)

This new meme coin has already raised over $26.7 million in its presale. Investors are excited about its potential, especially with its innovative Layer-2 ecosystem for meme tokens. Analysts predict a 100x gain once it hits exchanges.

$STARS (Crypto All-Stars)

Another new player in the meme coin space, Crypto All-Stars, is offering impressive yields of 479% per year through its MemeVault. The presale has already raised over $3.3 million, and investors are optimistic about its future performance.

$WIMI (WiMi Hologram Cloud)

WiMi Hologram Cloud Inc. has also been in the spotlight. The company, which specializes in augmented reality (AR) and virtual reality (VR) technologies, has announced a new partnership with a major tech firm to develop cutting-edge AR applications. This news has generated a lot of buzz among investors, and the stock has seen a steady rise in value over the past few weeks.

It's an exciting time for small cap stocks and the crypto market! Do you have any thoughts on these stocks or any other small cap gems you're keeping an eye on?

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

On Monday, the day before a med trial data announcement, RVPH opened around .90. On Tuesday leading up to the announcement, they opened around $1.10. Then, as I prayed 🙏🏻, a nice peak of $1.44 a couple hours after the announcement went well. Closed the day at $1.32.

At peak I had $7 in return on my 75.2 shares. For me I’m at a profit as long as they’re maintaining $1.33 per share, and after market hours have been hovering around that. Over all an 8.35% gain on my investment so far.

I’m still new to all this so this might just be a crazy theory, but it seems like the after market holds at whatever the day traders leave it at after they pull. Both Monday and Tuesday opened with the share price nearly the same as close. Which to me indicates that there’s an increased amount of people holding, and day traders are then going in and playing off the increased numbers.

You can see this with how even when it dips through out the day it never really goes below its stable peak of $1.33 since Monday. (Idk if that’s an actual thing, but what I mean is, $1.33 is the peak it’s maintaining despite $1.44 peaking the true peak)

I was initially day trading the stock, but after the second day Ive started to feel like I’m getting a good idea for how it trends through out the day. I’m planning on holding through today unless it drops below $1.30.

Part of why I’ve become bullish on this, is that after ABBVs schizophrenia med failed trails, it left BMY as the only notable company close to putting out a new schizophrenia medication. But now with RVPH proving to do well it shows healthy competition, and could be a good buying in price, especially compared to BMY, if you’re interested in psych pharma.

However it’s a healthcare penny stock, it could drop back down to .80 tomorrow for all I know. I’m just praying my DD proves me right.

Let me know if you wanna see any of my DD or have questions 🫡

125gge biofuel/ton of feedstock verified from fuels division

$325m SBC term sheet

3 Refineries coming

Silver rich materials leaving metals division by the truckload

Another facility coming for metals

Dayton and Lucerne

DOE? CRADA? NREL?

Revenue up from $0.8m to $1.4m

Sub just hit 100 members

Community on Stocktwits is abuzz

GenMat

Green Li-ion

Are the bears hibernating?

How is this team, their track records, and their mission so slept on?

Anyone else out there bullish on planetary health equating to generational wealth?

SAVE stock plummeted 60% because frontier decided to end all discussions of a merger with Spirit. I’m not usually a skeptic but something rotten is going on. First the prevented merger with JetBlue then Frontier suddenly dropping Sprite despite wanting to merge since 2022. Airline industry is corrupt and they just wanted to kick Spirit out so they can hike up prices.

https://www.wsj.com/business/airlines/spirit-airlines-moves-toward-bankruptcy-filing-after-frontier-drops-merger-bid-5d492e80

After becoming Caveat Emptor and going silent since 2017, the company quietly made 3 filings to the SEC in 2023 and another one this year. The CEO did his first interview on YouTube in over 10 years just a few weeks ago, talking about their activities for finding oil around Africa. He also has been posting a lot about oil on LinkedIn. Wondering if there's something huge on the horizon.

The Caveat Emptor that's been on the stock for the last 7 years - it wasn't due to the SEC, it was because Sao Tome where they got exclusive rights to a huge swath of land, they're not supposed to be publicly traded? At least that's how I interpreted it.

Links to the youtube video and one of the 8-K submissions:

• https://www.youtube.com/watch?v=-SWdglstGsY&t=34s
• https://capedge.com/filing/799235/0001376474-23-000512/ERHE-8K

I sometimes amuse myself by looking at once-great companies that went bust, and the Spirit downfall got me checking in on our Tupperware friends

Obviously TUP has very low liquidity now so the chart has lots of time with no price movement

Last week, it went up by hundreds of percentage points a couple of times, before falling back down. Just curious about what’s going on with these aggressive ups and downs in these OTC listings

Who’s buying a bankrupt company with a sub-$100K market cap? If you’re speculating and think you’re gonna make some money, who do you think will buy those shares from you when you want to cash out?

Been following this group for a bit and seen some of the stock you guys mention some of them have done amazing I was I would have found them months ago. Just wondering how you find them and what makes you confident to jump in

https://youtu.be/SLJjSIN1rLc?si=Wr9tjmPEwvJtu1UX

Hey everyone! I’ve been experimenting with Galileo FX, an automated trading bot, to help me trade penny stocks, and it’s been a really useful tool for handling the ups and downs of these volatile stocks. I got into penny stocks for the potential gains, but honestly, the swings can be stressful when you’re watching them all day. Galileo FX has made things so much easier by automating my trades and helping me manage risk.

The bot connects with MetaTrader 4 and 5, and it has settings that let you control your risk levels. I set mine to conservative, which helps limit losses if a stock goes the wrong way. It’s not going to make you rich overnight, but it’s steady, and that’s what I was looking for. Now I can focus on picking good stocks and let the bot handle the day-to-day moves for me.

If anyone’s looking for a tool to automate their penny stock trading and reduce some of the manual work, I’d say give Galileo FX a look. It’s been a great way to keep my trading more consistent without the stress of watching every price fluctuation!

Hey everyone, I'm looking into a ticker right now ticker is KAPA clinical stage bio pharmacy stock specializing in Cancer treatment when other treatments effectiveness starts to taper off Only 1.5M free float and trading under IPO price NO dilution fully funded trials!!! quoted saying

“Our technologies target a high value, large market - a fast growing $11.3 billion anti-androgen therapy prostate cancer market, $14 billion lung cancer market, and $118 billion immunotherapy market” IPOed at 4$ September 16th 2024 and is in my opinion undervalued, extreme confidence growing when phase 2 trials came back with a 62% clinical benefit when the expectation was 0% after resistance to cancer treatment occurred KAPA just received a grant from the National cancer Institute and has recently built a strategic relationship with Cedars-Sinai medical center #2 best hospital in America and hospital #1 in California gaining a lot of attention due to recent news and. I Vue this as a opportunity to Shair what I've found, thanks for reading!

Need some really sharp analysis here. Can it make it past $1?

I’ve been buying into the stock market for years, but right now I am trying to get more into penny stocks. I have some reading material to learn about it more, but what do you think is best to buy right now with regard to long term investing?

Also, in your personal experience, do you prefer quick buy and sell with penny stocks or waiting long term? Just curious where you guys seem to get the most profit and what your opinions are.

Thank you in advance

Hey everyone! I thought I’d share my experience using Galileo FX to automate some of my penny stock trades. I got into penny stocks because of the high potential returns, but managing them manually was a lot, especially with the volatility. Galileo FX has been a lifesaver in helping me keep up with these fast-moving trades and manage the risk automatically.

What’s been helpful for me is that Galileo FX lets you set up risk levels, so I don’t feel like I’m diving into every trade blindly. I’ve mostly kept it on conservative to avoid any big losses, but it still catches those nice little price jumps that we all look for in penny stocks. The bot is compatible with MetaTrader, so setup was quick, and it’s running while I’m doing other things—no need to be glued to my screen all day.

It’s not a magic solution (still have to make smart picks and keep an eye on the market), but it’s taken a lot of the stress out of trading these low-cost, high-risk stocks. Anyone else tried using a bot like Galileo FX for penny stocks? Curious if others have found it useful or have any tips for automation with these kinds of trades!

I tried to get a penny stock on Fidelity, but they said they would not let me because there was no company information listed for the ticker. OTC markets says it is only available for unsolicited customer orders-

https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/

How do I make an unsolicited order? I am not some kind of broker dealer myself.

I've been tracking Delta Resources and posting quite a bit, and their Delta-1 project in Ontario's Shebandowan Belt continues to impress with its scale and resource potential. A standout feature here is the Eureka Gold Deposit—a substantial and growing resource, not just a one-off find. Since beginning exploration in 2019, Delta has extended this deposit to a 2.5-kilometer strike length, delivering impressive results such as 15.94 g/t over 10 meters. Their 2023 drilling campaign included major intercepts like 4.23 g/t over 26.2 meters, underscoring the high-grade potential of this area.

A comment I keep receiving is that Delta needs to do more drilling and where they are going to get the funds to do so... at the end of last week Delta has secured financing at $0.30 per unit, above its current trading price 0f $0.125. This kind of financing is generally seen as a positive indicator in the market because it reflects investor confidence in the company’s value and potential upside. When a company is able to raise funds above the current share price, it suggests that investors see future potential and are willing to pay a premium based on expected progress. This financing looks like it could be the key to future drilling efforts!

The Shebandowan Belt, known for its history with significant players like Inco, holds untapped potential that Delta is strategically pursuing. Delta has increased its land position to 31,343 hectares, much of which has geological similarities to the Eureka zone. This extensive exploration effort and high-grade findings suggest that Delta-1 is more than just a promising project; it could be on the verge of a major discovery across this historic, gold-rich belt.

Disclaimer: This is not financial advice. Please do your own research before investing. 

I really wanted to get feedback on this trade. I thought that ESSA Pharma looked like a good buy since the stock came down a lot but they have very good cash flow.

I’ve been following Alaska Energy Metals (TSXV: AEMC) for some time due to my interest in EV’s and the inputs in battery production. Thought I would share some updates for those interested. Alaska has completed its second diamond drilling program at the Nikolai Nickel Project, located in Interior Alaska. The company drilled over 1,500 meters across four different holes, focusing on extending nickel-copper-cobalt mineralization in the Eureka Zone. This zone is already known to contain substantial nickel resources, with an estimate of over 3.9 billion pounds in the Indicated Category (813Mt @ 0.22% nickel) and over 4.2 billion pounds in the Inferred Category (896 Mt @ 0.21% nickel). 

This recently completed drilling program is significant as the nickel resource may grow substantially after the results are recevived. Nickel is a critical material in the production of electric vehicle (EV) batteries, and with the rapid growth of the EV market, there is increasing demand for stable, domestic nickel supplies. The data gathered from this drilling program will help the company better understand the mineralization patterns at Nikolai and may inform future exploration efforts. 

The results from this program are expected soon and could lead to important decisions regarding further resource development at the site. Alaska Energy Metals is positioning itself as a key player in supplying critical minerals necessary for the energy transition. 

Stock Info: TSXV: AEMC | OTCQB: AKEMF 

Disclaimer: This is not financial advice; please do your own research before investing. 

Quick Update on the Fundamentals

So what's going on these days with $MDAI and Spectral AI? Firstly, I'd like to highlight a split in the approaches we could use to value the short term prospects of the share price. We could look at business fundamentals and the value offered by the their much improving business fundamentals. Yes, there were not UK commercial sales confirmed as the market had expected by this earnings report, but the company does appear to be right on the cusp of commercial sales from their discussions with NICE. During the earnings call, much more emphasis was placed on the topline results of the US Burn Pivotal Study that are slated to release in December. This would be the first major indication of pre-commercial progress in the United States, the market that influences the share price most, and the FDA is going to be looking at these results carefully as part of their FDA submission to burn centers in Q2 2025.

If these study results are in line with past results or better, I'd expect a significant de-risking event for the market when considering the likelihood of FDA approval. As a reminder, Spectral AI has a very close partnership with BARDA (here's a short snippet explaining the nature of their partnership, https://www.youtube.com/watch?v=bKeCUuoRhqQ) in their funded development of the DeepView system. I personally believe it to be quite unlikely and borderline foolish to think that their DeepView system will not get regulatory approval in the US.

With regards to the financial state of the company, from their earnings 10-Q, "Based on our current operating plan, we believe that our cash and cash equivalents, together with the PBS BARDA Contract, the MTEC Agreement, the B. Riley ELOC, and the Yorkville Transaction, will be sufficient to fund operations for at least one year beyond the release date of these condensed consolidated financial statements."

This statement is an improvement over the last time the company has officially speculated on when they'd need more funding methods which was mid-2025. The company is receiving seems to be narrowing its research operational losses and is at least partly "due to a higher reimbursement rate under the PBS BARDA Contract, executed in September 2023, than the rate in the BARDA Burn II contact." Overall, the company is already starting off in a good place to executing their commercial plans, especially with founder DiMaio back at the helm whose focus is again "support[ing] the ongoing clinical development and commercialization of the Company’s DeepView® System, with particular focus on engagement with BARDA, the FDA, commercialization efforts and strategic relationships."

For a more comprehensive look at fundamentals, check out my previous posts and any of the analysts that cover this stock, easily readable reports are SP Angel with a $10 price target and Zacks with a $5 price target. Each have multiple updates.

The Spinoff Squeeze

Ok on to the other way of analyzing the short term prospects of the share price, the spinoff of Spectral IP and the naked shorts investigation. Earlier this week, Spectral AI announced that they'd be spinning off the IP protection subsidiary, Spectral IP, they've formed earlier this year in March to be headed by Erich Spangenberg, the largest current shareholder of MDAI stock and on the board of directors. The new chairman DiMaio (who is the second largest shareholder of MDAI stock by a large margin by the way) has stated the reasoning for this move is to enhance shareholder value by making the market reevaluate the different business components individually. On its own, not bad news at all for MDAI shareholders as spinoffs are known to be better performers on average and Spectral IP is not a significant portion of the Spectral AI business.

However, the company has requested the NASDAQ earlier this summer (twice, they're serious) for an investigation to be started to look into manipulation of the company stock by naked shorting, citing a discrepancy of 40% more shares being owned than issued by the company. If you are not familiar with naked shorting, this points to a large amount of synthetic shares making up that difference.

Putting the spinoff in the context of this naked short investigation that as far as the company knows has been taken up with FINRA, the spinoff shares being distributed in the form of a dividend to registered shareholders takes on a different meaning. Even with only registered shareholders getting their new spinoff shares, brokers are going to be under pressure to deliver spinoff shares to ALL shareholders by the record date, whether or not those shares are real or synthetic. The resolution to this should be a recall of the lent shares of naked short positions as the spinoff shares can only be delivered by the short sellers by having real shares in their account. This would mean a mass amount of buying of $MDAI shares to either not be on the hook for spinoff shares or to fulfill the delivery obligations while maintaining a short position. Either way, a mass amount of shares should have to be bought.

Spectral AI expects this spinoff to be completed within the next 90 days from the announcement, dependent upon approval from the board (obviously yes) and SEC (would wrap up the naked short investigation quite nicely). Furthermore, notice how the lead investigator in the company on the naked shorts investigation letters is also Erich Spangenberg. He is aware of how this spinoff could provide an immediate beneficial resolution to the short situation for his large stake in the company.

If Mr. Erich Spangenberg is this confident in this strategy to combat the naked short sellers, then so am I. May we hope for a squeeze similar to Overstock and take this post good earnings dip as an opportunity to load up under better information and outlook than before earnings. As always, let's discuss in the comments, I hope to hear your guys' perspectives.

I’ve been closely following ESGold’s Montauban Project, and there’s a lot to be excited about—especially when it comes to the untapped exploration potential in the region. ESGold not only has a well-established pathway to generate near-term cash flow, but they also hold significant upside with their 13,000-hectare land package. This project is poised to unlock substantial long-term growth, and it's clear the opportunity here is far from fully realized.

What really stands out is the Montauban Project's remarkable economics. With a projected 142% IRR (internal rate of return), ESGold is positioned for strong returns, thanks in part to their efficient processing infrastructure. The company’s plant, already set up to process 500 tonnes per day, gives them a solid foundation to generate revenue without infrastructure constraints. This means ESGold can quickly reinvest in further exploration, accelerating the value creation process without needing to dilute shareholders or scramble for funding.

The region itself is rich in Volcanogenic Massive Sulfide (VMS) deposits, known for containing high-grade metals like copper, gold, silver, and zinc. ESGold’s land package covers a significant portion of this highly prospective area, yet only a fraction of the land has been explored so far. Historical data points to near-surface, high-grade targets, which could bring substantial additional value to the project. It's like knowing there’s a treasure chest nearby, but only scratching the surface to uncover what’s inside.

With these impressive project economics and exploration potential, ESGold is well-positioned to become a key player in Quebec’s mining sector, and I’m watching closely as they move forward.

What's going on with this stock?

Lately, it's been rising sharply due to a report of positive net profits in 2025. Today, it had its first dip since that started, but I don't know if I want to purchase more.

Is Mogo a regular p & d or there more to it?

Key reasons for the move to Triller:

Music focus:

Triller positions itself as a more music-centric platform, appealing to creators who want to emphasize music videos and collaborations with artists.

Creator-centric approach:

Some influencers feel Triller is more receptive to creator feedback and offers better opportunities for monetization through brand partnerships.

Concerns about TikTok's ownership:

Some creators have expressed apprehension about data privacy due to TikTok's Chinese ownership, leading them to seek alternatives.

High-profile defections:

Notable TikTok stars like Josh Richards have publicly transitioned to Triller, encouraging their followers to join them.

They exceeded their North America revenue numbers by 45% based on their earnings report last week, while the industry only rose by 4%. They have a 26% growth year do date, also exceeding the market by quite a bit. Most experts have set a price range of $1.25-$3. This is not financial advice at all, but I like the current entry point.